Drugs / MIT-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05389696 | May 2022 → Feb 2023 | — | MitoImmune Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05493800 | Feb 2022 → Jun 2024 | chemotherapy-induced oral mucositis, plasma cell myeloma | MitoImmune Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT04651634 | Jun 2021 → Dec 2025 overdue | chemotherapy-induced oral mucositis, head and neck squamous cell carcinoma | MitoImmune Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIT-001 | “Single subcutaneous administration of 10mg MIT-001 or placebo” NCT05389696 ↗ |
| Route | Intravenous | “MIT-001 IV-infusion plus CCRT” NCT04651634 ↗ |